Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 11/20 | 0.62 |
| ▸ | BAZ2A | Q9UIF9 | 11/20 | 0.62 |
| ▸ | BRD4 | O60885 | 2/20 | 0.57 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.57 |
| ▸ | BRD2 | P25440 | 1/20 | 0.57 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | FNTA | P49354 | 2/20 | 0.44 |
| ▸ | FNTB | P49356 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29412239 | 0.81 | MAPT (0.68) | BAZ2BBAZ2ABRD4BRD9BRD2 | |
| SCHEMBL7439300 | 0.81 | BAZ2B (0.64) | BAZ2BBAZ2ABRD4BRD9BRD2 | |
| SCHEMBL25402450 | 0.80 | FNTA (0.68) | BAZ2BBAZ2ABRD4BRD2BRD3 | |
| SCHEMBL26302103 | 0.79 | BAZ2B (0.75) | BAZ2BBAZ2ABRD4BRD9BRD2 | |
| SCHEMBL25400578 | 0.78 | BAZ2B (0.45) | BAZ2BBAZ2ABRD4BRD9BRD2 | |
| SCHEMBL9531095 | 0.78 | FNTA (0.69) | BAZ2BBAZ2ABRD4BRD9BRD2 | |
| SCHEMBL26302091 | 0.76 | BAZ2B (0.74) | BAZ2BBAZ2ABRD4BRD9BRD2 | |
| SCHEMBL29547493 | 0.75 | FNTA (0.54) | BAZ2BBAZ2AMAPTTP53FNTA | |
| SCHEMBL24304134 | 0.74 | TP53 (0.63) | BAZ2BBAZ2ABRD4BRD9BRD2 | |
| SCHEMBL24510741 | 0.74 | BAZ2B (0.57) | BAZ2BBAZ2ABRD9TP53FNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4233864-B1 | COMPOSITION COMPRISING AN INDOLIZINE DERIVATIVE AND A CYCLIC DINUCLEOTIDE AS ACTIVE AGENTS | UNIV AJOU IND ACADEMIC COOP FOUND (KR) | 2025-02-12 | — | — | EP | disclosed |
| US-20230390319-A1 | INTERFERON GENE STIMULATOR COMPOSITION COMPRISING INDOLIZINE DERIVATIVE AS ACTIVE INGREDIENT | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-12-07 | — | — | US | disclosed |
| EP-4233864-A1 | INTERFERON GENE STIMULATOR COMPOSITION COMPRISING INDOLIZINE DERIVATIVE AS ACTIVE INGREDIENT | Ajou University Industry-Academic Cooperation Foundation (KR) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233864-A1 | INTERFERON GENE STIMULATOR COMPOSITION COMPRISING INDOLIZINE DERIVATIVE AS ACTIVE INGREDIENT | Ajou University Industry-Academic Cooperation Foundation (KR) | 2023-08-30 | — | — | EP | disclosed |
| WO-2022086260-A1 | INTERFERON GENE STIMULATOR COMPOSITION COMPRISING INDOLIZINE DERIVATIVE AS ACTIVE INGREDIENT | 아주대학교산학협력단 | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230390319-A1 | INTERFERON GENE STIMULATOR COMPOSITION COMPRISING INDOLIZINE DERIVATIVE AS ACTIVE INGREDIENT | STING1, IRF3, IFNG | BAZ2B 4487/4885BAZ2A 4020/4885BRD4 3042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.